Skip to main content
Erschienen in: Journal of Anesthesia 1/2020

18.09.2019 | Review Article

Medical cannabis for chronic pain: can it make a difference in pain management?

verfasst von: Mari Kannan Maharajan, Yu Jing Yong, Hong Yang Yip, Sze Shee Woon, Kar Mon Yeap, Khai Yeng Yap, Shuen Chi Yip, Kai Xian Yap

Erschienen in: Journal of Anesthesia | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Globally, chronic pain is a major therapeutic challenge and affects more than 15% of the population. As patients with painful terminal diseases may face unbearable pain, there is a need for more potent analgesics. Although opioid-based therapeutic agents received attention to manage severe pain, their adverse drug effects and mortality rate associated with opioids overdose are the major concerns. Evidences from clinical trials showed therapeutic benefits of cannabis, especially delta-9-tetrahydrocannabinol and cannabinoids reduced neuropathic pain intensity in various conditions. Also, there are reports on using combination cannabinoid therapies for chronic pain management. The association of cannabis dependence and addiction has been discussed much and the reports mentioned that it can be comparatively lower than other substances such as nicotine and alcohol. More countries have decided to legalise the medicinal use of cannabis and marijuana. Healthcare professionals should keep themselves updated with the changing state of medical cannabis and its applications. The pharmacokinetics and safety of medical cannabis need to be studied by conducting clinical research. The complex and variable chemically active contents of herbal cannabis and methodological limitations in the administration of cannabis to study participants, make the clinical research difficult.
Literatur
1.
Zurück zum Zitat Treede RD. The International Association for the Study of Pain definition of pain: as valid in 2018 as in 1979, but in need of regularly updated footnotes. Pain Rep. 2018;3(2):e643.PubMedPubMedCentral Treede RD. The International Association for the Study of Pain definition of pain: as valid in 2018 as in 1979, but in need of regularly updated footnotes. Pain Rep. 2018;3(2):e643.PubMedPubMedCentral
2.
Zurück zum Zitat Padfield D, Zakrzewska JM. Encountering pain. Lancet. 2017;389:1177–8.PubMed Padfield D, Zakrzewska JM. Encountering pain. Lancet. 2017;389:1177–8.PubMed
4.
Zurück zum Zitat Okifuji A, Turk DC. Philosophy and efficacy of multidisciplinary approach to chronic pain management. J Anesth. 1998;12:142–52.PubMed Okifuji A, Turk DC. Philosophy and efficacy of multidisciplinary approach to chronic pain management. J Anesth. 1998;12:142–52.PubMed
5.
Zurück zum Zitat Glare P, Aubrey KR, Myles PS. Transition from acute to chronic pain after surgery. Lancet. 2019;393:1537–46.PubMed Glare P, Aubrey KR, Myles PS. Transition from acute to chronic pain after surgery. Lancet. 2019;393:1537–46.PubMed
6.
Zurück zum Zitat Nugent SM, Morasco BJ, Oneil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu’apuaka M, Paynter BAR, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms. Ann Internal Med. 2017;167:319. Nugent SM, Morasco BJ, Oneil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu’apuaka M, Paynter BAR, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms. Ann Internal Med. 2017;167:319.
7.
Zurück zum Zitat Katz N, Paillard FC, Ekman E. Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions. J Orthop Surg Res. 2015;10:24.PubMedPubMedCentral Katz N, Paillard FC, Ekman E. Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions. J Orthop Surg Res. 2015;10:24.PubMedPubMedCentral
8.
Zurück zum Zitat Blackburn J. The diagnosis and management of chronic pain. Medicine. 2018;46:786–91. Blackburn J. The diagnosis and management of chronic pain. Medicine. 2018;46:786–91.
9.
Zurück zum Zitat Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755–E796796.PubMed Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755–E796796.PubMed
10.
Zurück zum Zitat Mitsi V, Zachariou V. Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience. 2016;338:81–92.PubMed Mitsi V, Zachariou V. Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience. 2016;338:81–92.PubMed
11.
Zurück zum Zitat Cazacu I, Mogosan C, Loghin F. Safety issues of current analgesics: an update. Med Pharm Rep. 2015;88:128–36. Cazacu I, Mogosan C, Loghin F. Safety issues of current analgesics: an update. Med Pharm Rep. 2015;88:128–36.
12.
Zurück zum Zitat Rosenquist E, Arson MD, Park L. Evaluation of chronic pain in adults. Up To Date. 2016;2016:1–14. Rosenquist E, Arson MD, Park L. Evaluation of chronic pain in adults. Up To Date. 2016;2016:1–14.
13.
Zurück zum Zitat Marshall B, Bland M, Hulla R, Gatchel R. Considerations in addressing the opioid epidemic and chronic pain within the USA. Pain Manag. 2019;2019:131–8. Marshall B, Bland M, Hulla R, Gatchel R. Considerations in addressing the opioid epidemic and chronic pain within the USA. Pain Manag. 2019;2019:131–8.
14.
Zurück zum Zitat Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;2008(16):405–16. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;2008(16):405–16.
15.
Zurück zum Zitat Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, Clauw DJ. Pills to Pot: observational analyses of cannabis substitution among medical cannabis users with chronic pain. J Pain. 2019;20:830–41.PubMed Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, Clauw DJ. Pills to Pot: observational analyses of cannabis substitution among medical cannabis users with chronic pain. J Pain. 2019;20:830–41.PubMed
16.
Zurück zum Zitat Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17:739–44.PubMed Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17:739–44.PubMed
17.
Zurück zum Zitat Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Internal Med. 2014;174:1668–733. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Internal Med. 2014;174:1668–733.
18.
Zurück zum Zitat Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proc Natl Acad Sci USA. 2019;116:12624–6.PubMedPubMedCentral Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proc Natl Acad Sci USA. 2019;116:12624–6.PubMedPubMedCentral
19.
Zurück zum Zitat Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Litchman AH. Δ9 Tetrahydrocannabinol accounts for the antinociceptive, hypothermic and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther. 2005;314:329–37.PubMed Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Litchman AH. Δ9 Tetrahydrocannabinol accounts for the antinociceptive, hypothermic and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther. 2005;314:329–37.PubMed
20.
Zurück zum Zitat Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169–72.PubMed Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169–72.PubMed
21.
Zurück zum Zitat Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ BMJ (Clinical Research Ed). 2019;365:11141. Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ BMJ (Clinical Research Ed). 2019;365:11141.
23.
Zurück zum Zitat Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol. 2019;30:98–102.PubMedPubMedCentral Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol. 2019;30:98–102.PubMedPubMedCentral
24.
Zurück zum Zitat Henschke P. Cannabis: an ancient friend or foe? What works and doesn't work. Semin Fetal Neonat Med. 2019;24:149–54. Henschke P. Cannabis: an ancient friend or foe? What works and doesn't work. Semin Fetal Neonat Med. 2019;24:149–54.
25.
Zurück zum Zitat Freundt-Revilla J, Kegler K, Baumgärtner W, Tipold A. Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS ONE. 2017;12:e0181064.PubMedPubMedCentral Freundt-Revilla J, Kegler K, Baumgärtner W, Tipold A. Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS ONE. 2017;12:e0181064.PubMedPubMedCentral
26.
Zurück zum Zitat Condie R, Herring A, Koh WS, Lee M, Kaminski NE. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem. 1996;271(22):13175–83.PubMed Condie R, Herring A, Koh WS, Lee M, Kaminski NE. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem. 1996;271(22):13175–83.PubMed
27.
Zurück zum Zitat Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006;3:S13–S1818. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006;3:S13–S1818.
28.
Zurück zum Zitat Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19:833.PubMedCentral Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19:833.PubMedCentral
29.
Zurück zum Zitat Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89:309–80.PubMed Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89:309–80.PubMed
30.
Zurück zum Zitat Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202.PubMed Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202.PubMed
31.
Zurück zum Zitat Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Cannabinoids. Handbook of experimental pharmacology. Berlin: Springer; 2005. p. 168. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Cannabinoids. Handbook of experimental pharmacology. Berlin: Springer; 2005. p. 168.
32.
Zurück zum Zitat Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735–44.PubMedPubMedCentral Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735–44.PubMedPubMedCentral
33.
Zurück zum Zitat Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. Eur J Internal Med. 2018;49:7–11. Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. Eur J Internal Med. 2018;49:7–11.
34.
Zurück zum Zitat MacCallum C, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Int Med. 2018;49:12–9. MacCallum C, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Int Med. 2018;49:12–9.
35.
Zurück zum Zitat Wiese B, Wilson-Poe AR. Emerging evidence for Cannabis' role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3:179–89.PubMedPubMedCentral Wiese B, Wilson-Poe AR. Emerging evidence for Cannabis' role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3:179–89.PubMedPubMedCentral
36.
Zurück zum Zitat Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–5.PubMed Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–5.PubMed
37.
Zurück zum Zitat Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2:160–6.PubMedPubMedCentral Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2:160–6.PubMedPubMedCentral
38.
Zurück zum Zitat Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study. Public Lib Sci One. 2017;12:e0187795. Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study. Public Lib Sci One. 2017;12:e0187795.
39.
Zurück zum Zitat Grant I, Atkinson JH, Gouaux B, Wilsey B. Medical marijuana: clearing away the smoke. Open Neurol J. 2012;6:18–25.PubMedPubMedCentral Grant I, Atkinson JH, Gouaux B, Wilsey B. Medical marijuana: clearing away the smoke. Open Neurol J. 2012;6:18–25.PubMedPubMedCentral
40.
Zurück zum Zitat Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. J Am Med Assoc. 2015;313:2474–83. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. J Am Med Assoc. 2015;313:2474–83.
41.
Zurück zum Zitat Larriviere DG. Medical marijuana for HIV-associated sensory neuropathy: legal and ethical issues. Continuum (Minneap Minn). 2014;20:1426–9. Larriviere DG. Medical marijuana for HIV-associated sensory neuropathy: legal and ethical issues. Continuum (Minneap Minn). 2014;20:1426–9.
42.
Zurück zum Zitat Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34:672–80.PubMed Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34:672–80.PubMed
43.
Zurück zum Zitat Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506–21.PubMedPubMedCentral Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506–21.PubMedPubMedCentral
44.
Zurück zum Zitat Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515–21.PubMed Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515–21.PubMed
45.
Zurück zum Zitat Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517–26.PubMed Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517–26.PubMed
46.
Zurück zum Zitat Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:53. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:53.
47.
Zurück zum Zitat Noyes R Jr, Baram DA. Cannabis analgesia. Compr Psychiatry. 1974;15:531–5.PubMed Noyes R Jr, Baram DA. Cannabis analgesia. Compr Psychiatry. 1974;15:531–5.PubMed
48.
Zurück zum Zitat Noyes R, Brunk S, Avery D, Canter A. The analgesic properties of delta-9-tertrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84–9.PubMed Noyes R, Brunk S, Avery D, Canter A. The analgesic properties of delta-9-tertrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84–9.PubMed
49.
Zurück zum Zitat Perron BE, Bohnert K, Perone AK, Bonn-Miller MO, Ilgen M. Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use. J Stud Alcohol Drugs. 2015;76:406–13.PubMedPubMedCentral Perron BE, Bohnert K, Perone AK, Bonn-Miller MO, Ilgen M. Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use. J Stud Alcohol Drugs. 2015;76:406–13.PubMedPubMedCentral
50.
Zurück zum Zitat Pergolizzi JV Jr, Lequang JA, Taylor R Jr, Raffa RB, Colucci D, NEMA Research Group. The role of cannabinoids in pain control: the good, the bad, and the ugly. Miner Anestesiol. 2018;84:955–69. Pergolizzi JV Jr, Lequang JA, Taylor R Jr, Raffa RB, Colucci D, NEMA Research Group. The role of cannabinoids in pain control: the good, the bad, and the ugly. Miner Anestesiol. 2018;84:955–69.
51.
Zurück zum Zitat Boehnke KF, Gangopadhyay S, Clauw DJ, Haffajee RL. Qualifying conditions of medical cannabis license holders in the United States. Health Aff. 2019;38:295–302. Boehnke KF, Gangopadhyay S, Clauw DJ, Haffajee RL. Qualifying conditions of medical cannabis license holders in the United States. Health Aff. 2019;38:295–302.
52.
Zurück zum Zitat Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, Lindblad AJ, Korownyk C, Kolber MR. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64:e78–94.PubMedPubMedCentral Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, Lindblad AJ, Korownyk C, Kolber MR. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64:e78–94.PubMedPubMedCentral
53.
Zurück zum Zitat Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, Sacks HS. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16:1221–322.PubMedPubMedCentral Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, Sacks HS. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16:1221–322.PubMedPubMedCentral
54.
Zurück zum Zitat Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14:136–48.PubMed Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14:136–48.PubMed
55.
Zurück zum Zitat Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane database of systematic reviews. 2018. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane database of systematic reviews. 2018.
56.
Zurück zum Zitat Hill K, Palastro M, Johnson B, Ditre J. Cannabis and pain: a clinical review. Cannabis Cannabinoid Res. 2017;2:96–104.PubMedPubMedCentral Hill K, Palastro M, Johnson B, Ditre J. Cannabis and pain: a clinical review. Cannabis Cannabinoid Res. 2017;2:96–104.PubMedPubMedCentral
57.
Zurück zum Zitat Häuser W, Fitzcharles M, Radbruch L, Petzke F. Cannabinoids in pain management and palliative medicine. Deutsches Arzteblatt Int. 2017;114:627–34. Häuser W, Fitzcharles M, Radbruch L, Petzke F. Cannabinoids in pain management and palliative medicine. Deutsches Arzteblatt Int. 2017;114:627–34.
58.
Zurück zum Zitat Queensland Government. Clinical guidance: for the use of medicinal cannabis products in Queensland. 2018. Queensland Government. Clinical guidance: for the use of medicinal cannabis products in Queensland. 2018.
59.
Zurück zum Zitat Bargnes V, Hart P, Gupta S, Mechtler L. Safety and efficacy of medical cannabis in elderly patients: a retrospective review in a neurological outpatient setting. Neurology. 2019;92:1–14. Bargnes V, Hart P, Gupta S, Mechtler L. Safety and efficacy of medical cannabis in elderly patients: a retrospective review in a neurological outpatient setting. Neurology. 2019;92:1–14.
60.
Zurück zum Zitat Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, Bisaga A, Comer S, Nunes EV. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict. 2009;18:301–8.PubMedPubMedCentral Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, Bisaga A, Comer S, Nunes EV. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict. 2009;18:301–8.PubMedPubMedCentral
61.
Zurück zum Zitat Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, Nielsen S, Cohen M, Chan G, Mattick RP, Blyth F, Shanahan M, Dobbins T, Farrell M, Degenhardt L. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3:e341–e350350.PubMedPubMedCentral Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, Nielsen S, Cohen M, Chan G, Mattick RP, Blyth F, Shanahan M, Dobbins T, Farrell M, Degenhardt L. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3:e341–e350350.PubMedPubMedCentral
62.
Zurück zum Zitat Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, Degenhardt L. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159:1932–54.PubMed Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, Degenhardt L. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159:1932–54.PubMed
63.
Zurück zum Zitat Wang T, Collet J, Shapiro S, Ware M. Adverse effects of medical cannabinoids: a systematic review. Can Med Assoc J. 2008;178:1669–788. Wang T, Collet J, Shapiro S, Ware M. Adverse effects of medical cannabinoids: a systematic review. Can Med Assoc J. 2008;178:1669–788.
64.
Zurück zum Zitat Volkow N, Baler R, Compton W, Weiss S. Adverse health effects of marijuana use. N Engl J Med. 2017;370:2219–27. Volkow N, Baler R, Compton W, Weiss S. Adverse health effects of marijuana use. N Engl J Med. 2017;370:2219–27.
65.
Zurück zum Zitat Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for medical use. J Am Med Assoc. 2015;313:2456. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for medical use. J Am Med Assoc. 2015;313:2456.
66.
Zurück zum Zitat Ware MA, Wang T, Shapiro S, Collet JP, COMPASS Study Team. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;2015(16):1233–42. Ware MA, Wang T, Shapiro S, Collet JP, COMPASS Study Team. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;2015(16):1233–42.
67.
Zurück zum Zitat Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R. Effects of cannabis use on human behavior, including cognition, motivation and psychosis: a review. J Am Med Assoc Psychiatry. 2016;73:292–7. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R. Effects of cannabis use on human behavior, including cognition, motivation and psychosis: a review. J Am Med Assoc Psychiatry. 2016;73:292–7.
68.
Zurück zum Zitat Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ. Effects of chronic, heavy cannabis use on executive functions. J Addict Med. 2011;5:9–15.PubMedPubMedCentral Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ. Effects of chronic, heavy cannabis use on executive functions. J Addict Med. 2011;5:9–15.PubMedPubMedCentral
69.
Zurück zum Zitat Fernández-Ruiz J, Hernández M, Ramos JA. Cannabinoid–dopamine interaction in the pathophysiology and treatment of CNS disorder. CNS Neurosci Ther. 2010;16:e72–91.PubMedPubMedCentral Fernández-Ruiz J, Hernández M, Ramos JA. Cannabinoid–dopamine interaction in the pathophysiology and treatment of CNS disorder. CNS Neurosci Ther. 2010;16:e72–91.PubMedPubMedCentral
70.
Zurück zum Zitat Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh S. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39–47.PubMed Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh S. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39–47.PubMed
71.
Zurück zum Zitat Lenné M, Dietze P, Triggs T, Walmsley S, Murphy B, Redman J. The effects of cannabis and alcohol on simulated arterial driving: influences of driving experience and task demand. Accid Anal Prev. 2010;42:859–66.PubMed Lenné M, Dietze P, Triggs T, Walmsley S, Murphy B, Redman J. The effects of cannabis and alcohol on simulated arterial driving: influences of driving experience and task demand. Accid Anal Prev. 2010;42:859–66.PubMed
72.
Zurück zum Zitat Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction. 2016;111:1348–59.PubMed Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction. 2016;111:1348–59.PubMed
73.
Zurück zum Zitat Schreiner A, Dunn M. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012;20:420–9.PubMed Schreiner A, Dunn M. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012;20:420–9.PubMed
74.
Zurück zum Zitat Zalesky A, Solowij N, Yücel M, Lubman DI, Takagi M, Harding IH, Lorenzetti V, Wang R, Searle K, Pantelis C, Seal M. Effect of long-term cannabis use on axonal fibre connectivity. Brain. 2012;135:2245–55.PubMed Zalesky A, Solowij N, Yücel M, Lubman DI, Takagi M, Harding IH, Lorenzetti V, Wang R, Searle K, Pantelis C, Seal M. Effect of long-term cannabis use on axonal fibre connectivity. Brain. 2012;135:2245–55.PubMed
75.
Zurück zum Zitat Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci. 2012;109:E2657–E26642664.PubMedPubMedCentral Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci. 2012;109:E2657–E26642664.PubMedPubMedCentral
76.
Zurück zum Zitat Simonetto D, Oxentenko A, Herman M, Szostek J. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012;87:114–9.PubMedPubMedCentral Simonetto D, Oxentenko A, Herman M, Szostek J. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012;87:114–9.PubMedPubMedCentral
77.
Zurück zum Zitat Sorensen C, DeSanto K, Borgelt L, Phillips K, Monte A. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. J Med Toxicol. 2016;13:71–877.PubMedPubMedCentral Sorensen C, DeSanto K, Borgelt L, Phillips K, Monte A. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. J Med Toxicol. 2016;13:71–877.PubMedPubMedCentral
78.
Zurück zum Zitat Uranga JA, Vera G, Abalo R. Cannabinoid pharmacology and therapy in gut disorders. Biochem Pharmacol. 2018;2018(157):134–7. Uranga JA, Vera G, Abalo R. Cannabinoid pharmacology and therapy in gut disorders. Biochem Pharmacol. 2018;2018(157):134–7.
79.
Zurück zum Zitat Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci. 2010;55:3113–9.PubMed Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci. 2010;55:3113–9.PubMed
80.
Zurück zum Zitat Prud'homme M, Cata R, Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Substance Abuse Res Treat. 2015;9:33–8. Prud'homme M, Cata R, Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Substance Abuse Res Treat. 2015;9:33–8.
81.
Zurück zum Zitat Bushra R, Aslam N, Ahmed KZ. Drug misuse, dependence and addiction. J Appl Pharm Sci. 2013;3:1–7. Bushra R, Aslam N, Ahmed KZ. Drug misuse, dependence and addiction. J Appl Pharm Sci. 2013;3:1–7.
82.
Zurück zum Zitat Lopez-Quintero C, Perez le dos Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115:120–30.PubMed Lopez-Quintero C, Perez le dos Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115:120–30.PubMed
83.
Zurück zum Zitat George T, Vaccarino F. Substance abuse in Canada: the effects of cannabis use during adolescence. Ottawa; 2015. George T, Vaccarino F. Substance abuse in Canada: the effects of cannabis use during adolescence. Ottawa; 2015.
84.
Zurück zum Zitat Kandel D, Chen K, Warner LA, Kesslerm RC, Grant B. Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the US population. Drug Alcohol Depend. 1997;44:11–29.PubMed Kandel D, Chen K, Warner LA, Kesslerm RC, Grant B. Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the US population. Drug Alcohol Depend. 1997;44:11–29.PubMed
85.
Zurück zum Zitat Lev-Ran S, Le Strat Y, Imtiaz S, Rehm J, Le Foll B. Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. Am J Addict. 2013;22:7–13.PubMed Lev-Ran S, Le Strat Y, Imtiaz S, Rehm J, Le Foll B. Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. Am J Addict. 2013;22:7–13.PubMed
86.
Zurück zum Zitat Schlossarek S, Kempkensteffen J, Reimer J, Verthein U. Psychosocial determinants of cannabis dependence: a systematic review of the literature. Eur Addict Res. 2015;22:131–44.PubMed Schlossarek S, Kempkensteffen J, Reimer J, Verthein U. Psychosocial determinants of cannabis dependence: a systematic review of the literature. Eur Addict Res. 2015;22:131–44.PubMed
87.
Zurück zum Zitat Hall W, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry. 2007;20:393–7.PubMed Hall W, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry. 2007;20:393–7.PubMed
88.
Zurück zum Zitat Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47.PubMed Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47.PubMed
89.
Zurück zum Zitat Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology. 2004;47:24–322.PubMed Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology. 2004;47:24–322.PubMed
90.
Zurück zum Zitat Chen-Yu C, Storr CL, Anthony JC. Early-onset drug use and risk for drug dependence problems. Addict Behav. 2009;34:319–22. Chen-Yu C, Storr CL, Anthony JC. Early-onset drug use and risk for drug dependence problems. Addict Behav. 2009;34:319–22.
91.
Zurück zum Zitat Le Strat Y, Ramoz N, Horwood J, Falissard B, Hassler C, Romo L, Choquet M, Fergusson D, Gorwood P. First positive reactions to cannabis constitute a priority risk factor for cannabis dependence. Addiction. 2009;104:1710–7.PubMed Le Strat Y, Ramoz N, Horwood J, Falissard B, Hassler C, Romo L, Choquet M, Fergusson D, Gorwood P. First positive reactions to cannabis constitute a priority risk factor for cannabis dependence. Addiction. 2009;104:1710–7.PubMed
92.
Zurück zum Zitat van der Pol P, Liebregts N, de Graaf R, Ten Have M, Korf DJ, van den Brink W, van Laar M. Mental health differences between frequent cannabis users with and without dependence and the general population. Addiction. 2013;108:1459–69.PubMed van der Pol P, Liebregts N, de Graaf R, Ten Have M, Korf DJ, van den Brink W, van Laar M. Mental health differences between frequent cannabis users with and without dependence and the general population. Addiction. 2013;108:1459–69.PubMed
93.
Zurück zum Zitat Zolotov Y, Vulfsons S, Zarhin D, Sznitman S. Medical cannabis: an oxymoron? Physicians’ perceptions of medical cannabis. Int J Drug Policy. 2018;57:4–10.PubMed Zolotov Y, Vulfsons S, Zarhin D, Sznitman S. Medical cannabis: an oxymoron? Physicians’ perceptions of medical cannabis. Int J Drug Policy. 2018;57:4–10.PubMed
94.
Zurück zum Zitat Sznitman SN, Lewis N. Is cannabis an illicit drug or a medicine? A quantitative framing analysis of Israeli newspaper coverage. Int J Drug Policy. 2015;26:446–52.PubMed Sznitman SN, Lewis N. Is cannabis an illicit drug or a medicine? A quantitative framing analysis of Israeli newspaper coverage. Int J Drug Policy. 2015;26:446–52.PubMed
95.
Zurück zum Zitat Fischer B, Kuganesan S, Room R. Medical marijuana programs: implications for cannabis control policy—observations from Canada. Int J Drug Policy. 2015;26:15–9.PubMed Fischer B, Kuganesan S, Room R. Medical marijuana programs: implications for cannabis control policy—observations from Canada. Int J Drug Policy. 2015;26:15–9.PubMed
96.
Zurück zum Zitat Park JY, Wu LT. Prevalence, reasons, perceived effects, and correlates of medical marijuana use: a review. Drug Alcohol Depend. 2017;177:1–13.PubMedPubMedCentral Park JY, Wu LT. Prevalence, reasons, perceived effects, and correlates of medical marijuana use: a review. Drug Alcohol Depend. 2017;177:1–13.PubMedPubMedCentral
97.
Zurück zum Zitat Ebbert J, Scharf E, Hurt R. Medical cannabis. Mayo Clin Proc. 2018;93:1842–7.PubMed Ebbert J, Scharf E, Hurt R. Medical cannabis. Mayo Clin Proc. 2018;93:1842–7.PubMed
98.
Zurück zum Zitat European Monitoring Centre for Drugs and Drug Addiction. Medical use of cannabis and cannabinoids: questions and answers for policymaking. Luxembourg: Publications Office of the European Union; 2018. European Monitoring Centre for Drugs and Drug Addiction. Medical use of cannabis and cannabinoids: questions and answers for policymaking. Luxembourg: Publications Office of the European Union; 2018.
99.
Zurück zum Zitat Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Marijuana legalization: impact on physicians and public health. Annu Rev Med. 2016;67:453–66.PubMed Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Marijuana legalization: impact on physicians and public health. Annu Rev Med. 2016;67:453–66.PubMed
100.
Zurück zum Zitat Carliner H, Brown Q, Sarvet A, Hasin D. Cannabis use, attitudes, and legal status in the US: a review. Prev Med. 2017;104:13–23.PubMedPubMedCentral Carliner H, Brown Q, Sarvet A, Hasin D. Cannabis use, attitudes, and legal status in the US: a review. Prev Med. 2017;104:13–23.PubMedPubMedCentral
101.
Zurück zum Zitat Olam K, Goldschmidt D. Thailand approves medical marijuana. Cable News Netw Health. 2018. Olam K, Goldschmidt D. Thailand approves medical marijuana. Cable News Netw Health. 2018.
103.
Zurück zum Zitat Aguilar S, Gutiérrez V, Sánchez L, Nougier M. Medicinal cannabis policies and practices around the world, IDPC Briefing Paper. London: IDC; 2018. Aguilar S, Gutiérrez V, Sánchez L, Nougier M. Medicinal cannabis policies and practices around the world, IDPC Briefing Paper. London: IDC; 2018.
104.
Zurück zum Zitat The Commissioner of Law Revision, Malaysia (1980) Dangerous Drug Act 1952. The Commissioner of Law Revision, Malaysia (1980) Dangerous Drug Act 1952.
105.
Zurück zum Zitat Savage S, Romero-Sandoval A, Schatman M, Wallace M, Fanciullo G, McCarberg B, Ware M. Cannabis in pain treatment: clinical and research considerations. J Pain. 2016;17:654–68.PubMed Savage S, Romero-Sandoval A, Schatman M, Wallace M, Fanciullo G, McCarberg B, Ware M. Cannabis in pain treatment: clinical and research considerations. J Pain. 2016;17:654–68.PubMed
106.
Zurück zum Zitat National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: National Academies Press; 2017. National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: National Academies Press; 2017.
107.
Zurück zum Zitat National Institute on Drug Abuse. 2016–2020 NIDA Strategic Plan; NIDA mission: 2016. National Institute on Drug Abuse. 2016–2020 NIDA Strategic Plan; NIDA mission: 2016.
108.
Zurück zum Zitat National Institute on Drug Abuse. NIH research on marijuana and cannabinoids: 2018. National Institute on Drug Abuse. NIH research on marijuana and cannabinoids: 2018.
109.
Zurück zum Zitat Thomas B, Pollard G. Preparation and distribution of cannabis and cannabis-derived dosage formulations for investigational and therapeutic use in the United States. Front Pharmacol. 2016;7:285.PubMedPubMedCentral Thomas B, Pollard G. Preparation and distribution of cannabis and cannabis-derived dosage formulations for investigational and therapeutic use in the United States. Front Pharmacol. 2016;7:285.PubMedPubMedCentral
110.
Zurück zum Zitat Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J Pain Palliative Care Pharmacother. 2014;28:216–25. Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J Pain Palliative Care Pharmacother. 2014;28:216–25.
111.
Zurück zum Zitat Boehnke KF, Scott JR, Litinas E, Sisley S, Clauw DJ, Goesling J, Williams DA. Cannabis use preferences and decision-making among a cross-sectional cohort of medical cannabis patients with chronic pain. J Pain. 2019; pii: S1526–5900(19)30067–7. Boehnke KF, Scott JR, Litinas E, Sisley S, Clauw DJ, Goesling J, Williams DA. Cannabis use preferences and decision-making among a cross-sectional cohort of medical cannabis patients with chronic pain. J Pain. 2019; pii: S1526–5900(19)30067–7.
Metadaten
Titel
Medical cannabis for chronic pain: can it make a difference in pain management?
verfasst von
Mari Kannan Maharajan
Yu Jing Yong
Hong Yang Yip
Sze Shee Woon
Kar Mon Yeap
Khai Yeng Yap
Shuen Chi Yip
Kai Xian Yap
Publikationsdatum
18.09.2019
Verlag
Springer Singapore
Erschienen in
Journal of Anesthesia / Ausgabe 1/2020
Print ISSN: 0913-8668
Elektronische ISSN: 1438-8359
DOI
https://doi.org/10.1007/s00540-019-02680-y

Weitere Artikel der Ausgabe 1/2020

Journal of Anesthesia 1/2020 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.